Shares of HCA Healthcare, Inc. ( HCA ) have been a strong performer over the past year, gaining over 40%. The company has used buybacks to aggressively reduce share count while also steadily expanding operating margins, creating a favorable environment for shares. A solid Q4Over fifteen years of experience making contrarian bets based on my macro view and stock-specific turnaround stories to garner outsized returns with a favorable risk/reward profile. If you want me to cover a specific stock or have a ques ...

Core Insights - HCA Healthcare reported revenue of $19.51 billion for the quarter ended December 2025, reflecting a year-over-year increase of 6.7% [1] - The earnings per share (EPS) for the quarter was $8.01, up from $6.22 in the same quarter last year, with an EPS surprise of +8.9% compared to the consensus estimate of $7.36 [1] - The reported revenue was slightly below the Zacks Consensus Estimate of $19.64 billion, resulting in a revenue surprise of -0.63% [1] Financial Performance Metrics - Revenue per Equivalent Admission was $18,794, slightly below the average estimate of $18,847.16 [4] - Equivalent Admissions were reported at 1.04 billion, matching the average estimate [4] - Total Admissions reached 576.84 million, slightly above the average estimate of 575.8 million [4] - Patient Days totaled 2,708.66, marginally exceeding the estimate of 2,704.34 [4] - The Average Length of Stay remained consistent at 5 days, in line with estimates [4] - The number of hospitals was reported at 190, slightly below the estimate of 191 [4] - Inpatient Revenue per Admission was $19,847, significantly lower than the average estimate of $20,470.97 [4] - Equivalent Patient Days were 4.88 million, just below the average estimate of 4.89 million [4] - Licensed Beds at the end of the period were 50,436, below the estimate of 50,574 [4] - The number of freestanding outpatient surgery centers was 121, below the average estimate of 123 [4] Stock Performance - HCA shares have returned -0.4% over the past month, contrasting with the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Group 1: HCA Healthcare Inc - HCA Healthcare reported fourth-quarter adjusted EPS of $8.01, exceeding the analyst consensus estimate of $7.43 [1] - Following the earnings report, HCA Healthcare shares increased by 9.5% to $517.00 [1] - The company raised its FY25 guidance above estimates, indicating positive future expectations [1] Group 2: Other Notable Stock Movements - SuperX AI Technology Ltd shares surged by 27.1% to $16.79 [3] - Redwire Corp gained 21.4% to $13.29 after securing a contract worth up to $151 billion for missile defense [3] - HUYA Inc saw a 14.9% increase to $4.12 [3] - Cloudflare Inc shares rose by 14.5% to $216.99 [3] - Regencell Bioscience Holdings Ltd gained 13.5% to $33.13 [3] - Gold.com Inc surged 13.5% to $50.00 [3] - Corning Inc increased by 12.4% to $106.78 following a $6 billion agreement with Meta [3] - General Motors Co reported better-than-expected quarterly adjusted EPS results and raised its dividend, leading to a 6.8% increase to $84.84 [3]

Core Insights - UnitedHealth Group reported consolidated revenues of $447.6 billion for 2025, reflecting a 12% year-over-year growth, and provided an optimistic outlook for 2026 with projected revenues exceeding $439.0 billion [2][10][23] - The company emphasized its commitment to improving operational transparency and performance, which is expected to enhance its service delivery and growth trajectory [4][19] Financial Performance - For 2025, earnings from operations were $19.0 billion with a net margin of 2.7%, while cash flows from operations reached $19.7 billion, equating to 1.5 times net income [2][10] - The adjusted earnings from operations for 2025 were reported at $21.7 billion, excluding a $2.8 billion charge related to cyberattack costs and restructuring efforts [10][30] Segment Performance - UnitedHealthcare served 49.8 million consumers in 2025, generating revenues of $344.9 billion, a 16% increase from the previous year [6][15] - Optum's revenues grew by 7% to $270.6 billion, supporting over 123 million consumers across its various businesses [6][12] 2026 Outlook - The company anticipates earnings from operations to exceed $24.0 billion in 2026, with an adjusted earnings outlook greater than $17.75 per share [21][23] - The projected medical care ratio for 2026 is expected to improve to 88.8%, reflecting ongoing repricing efforts and operational efficiencies [23][27] Operational Changes - UnitedHealth Group has implemented measures to enhance operational transparency, including independent reviews of business practices [4] - The company is focusing on aligning pricing strategies with higher medical trends and health care policy changes to ensure sustainable growth [6][10]

Core Insights - Alrajhi Medicine is partnering with Oracle to implement Oracle Health Foundation EHR and Oracle Fusion Cloud Applications to enhance operational efficiency and support growth in its healthcare network [1][2][4] Company Overview - Alrajhi Medicine is a private healthcare network in Saudi Arabia, part of Abdullah Sulaiman Al Rajhi Holding (ASAQ), aiming to develop a network of modern hospitals and specialized medical centers across the Kingdom [6] Technology Adoption - Alrajhi Medicine becomes the first private healthcare group in Saudi Arabia to adopt Oracle Health and Oracle Fusion Applications as a unified digital platform, integrating clinical and business operations [2][3] - The implementation of Oracle technologies will create a fully connected ecosystem across hospitals and clinics, facilitating better data sharing and decision-making [3][4] Strategic Goals - The collaboration aims to transform digital operations and improve healthcare delivery, positioning Alrajhi Medicine as a leader in smart healthcare systems within the private sector in Saudi Arabia [4][5] - The Oracle Health Foundation EHR will enhance care coordination and communication, while reducing administrative tasks for clinicians, allowing them to focus more on patient care [4] Future Growth - Oracle's solutions are designed to scale with Alrajhi Medicine's expansion, supporting continuous innovation and setting a new benchmark for intelligent healthcare in the Middle East [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities between July 18, 2024, and November 12, 2025, of the March 9, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Ardent Health securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 9, 2026, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, as many firms may lack the necessary experience [4]. - The firm has a history of significant recoveries for investors, including over $438 million in 2019 alone, and has been recognized for its leadership in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable, claiming to employ an active monitoring process that was not actually utilized [5]. - Defendants reportedly downplayed issues related to increased claim denials by third-party payors and did not write off uncollectible accounts as required [5]. - The firm also failed to maintain sufficient professional malpractice liability insurance, which was inadequate to cover claims arising from operations, particularly in the New Mexico market [5].

Company Overview - Astrana Health, Inc. is a leading provider-centric, technology-powered healthcare company focused on delivering accessible, high-quality, and high-value care [1][4] - The company supports over 20,000 providers and more than 1.6 million patients in value-based care arrangements through its affiliated networks and integrated care delivery clinics [5] Financial Results Announcement - Astrana Health will release its financial results for the fourth quarter and year ended December 31, 2025, before the stock market opens on March 2, 2026 [1] - A conference call to discuss these results will take place at 5:30 a.m. PT / 8:30 a.m. ET on the same day [1] Accessing the Conference Call - Participants can dial in to the conference call using the numbers 877-858-9810 or +1 201-689-8517, and should join approximately five minutes before the start time [2] - An accompanying slide presentation will be available in PDF format on the company's "IR Calendar" page after the earnings release [2] Webcast Information - The conference call will also be available via online webcast, with a recording accessible shortly after the call concludes [3]

Core Viewpoint - The agreement between Pulsenmore and Clalit aims to revolutionize fertility care by allowing patients to perform follicular monitoring scans from home, enhancing convenience and maintaining clinical oversight [1][4]. Group 1: Agreement Details - Pulsenmore and Clalit will establish an end-to-end clinical service through Beilinson NEXT, enabling eligible patients to conduct follicular monitoring scans at home with real-time guidance [1]. - The agreement allows both companies to market Pulsenmore FC directly to patients, facilitating access to at-home fertility monitoring [1]. Group 2: Product Overview - Pulsenmore FC is a patient-operated ultrasound device designed for at-home follicular monitoring, transmitting scan data securely to the Beilinson NEXT care team for remote interpretation [3]. - The device aims to reduce the need for frequent in-clinic visits during IVF and fertility preservation cycles, thus minimizing disruption to patients' daily lives [3]. Group 3: Clinical Study Results - A controlled clinical study at Beilinson Medical Center reported a strong safety profile for Pulsenmore FC, showing high concordance between at-home measurements and in-clinic assessments [2]. Group 4: Strategic Vision - Clalit’s CEO emphasized that the new service aligns with their strategic vision of providing medical services from home, ensuring quality comparable to hospital settings [5]. - The service is expected to enhance the experience for women and couples undergoing fertility treatments, addressing the emotional and physical complexities involved [5]. Group 5: Future Developments - Pulsenmore has also supplied Clalit with its physician-supervised home prenatal ultrasound solution, Pulsenmore ES, which has received FDA De Novo authorization [5]. - A binding agreement for an additional 25,000 Pulsenmore ES units over five years has been signed, indicating a commitment to expanding their service offerings [5].

Investment Rating - The report indicates a positive outlook for the private equity (PE) industry, highlighting a resurgence in deal activity and a strong market environment, suggesting a favorable investment rating for the sector in 2025 [8][9]. Core Insights - The private equity sector experienced a significant rebound in 2025, with total deal activity surpassing 9,000 transactions and an aggregate value of approximately $1.2 trillion, marking only the second time in history that deal value exceeded $1 trillion [8][34]. - The second half of 2025 saw a strong recovery in deal flow, compensating for a slowdown in Q2 due to market volatility, with 4,560 deals valued at $632.2 billion [35]. - The report emphasizes the importance of mega-sized transactions, with 150 megadeals totaling $567.8 billion, surpassing previous years and indicating a strong appetite for large-scale investments [9][34]. Summary by Sections Executive Summary - The PE industry rebounded strongly in 2025, achieving a total deal value of $1,155.5 billion, with a year-over-year growth of 36.3% [7]. - Exit activity also saw significant growth, with exit values reaching $728.1 billion, a 90.1% increase from the previous year [7]. Deals - The total number of PE deals in 2025 was 9,019, with a deal count increase of 5.9% year-over-year [7]. - Buyout/LBO transactions accounted for $616.6 billion, reflecting a 57.4% increase compared to 2024 [7]. Fundraising - Fundraising in 2025 was noted as the weakest since 2020, with significant declines in both fund count and capital raised, despite increasing exit activity [12]. - The dry powder in the PE market reached an all-time high of $1.1 trillion, indicating potential for future deal-making [12]. Performance - The report highlights a bifurcation in the market, with large, high-conviction investments performing well, while lower and middle market activities remained muted [72]. - The healthcare sector saw a notable increase in deal value, driven by a few mega-transactions, with a 43.4% rise in total PE-backed healthcare deal value [72]. Valuations - Median global M&A EV/EBITDA multiples reached 10x, recovering from previous lows and indicating a strong valuation environment for PE deals [81]. - PE buyout valuations showed a mixed trend, with EBITDA multiples adjusting down slightly to 12.3x, while revenue multiples increased significantly to 2.5x [82].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Ardent Health, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - The Class Period for the Ardent Health securities is from July 18, 2024, to November 12, 2025, inclusive [1] - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by March 9, 2026 [2] Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [3] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for clients [3] Group 3: Case Allegations - The lawsuit alleges that Ardent Health made misrepresentations regarding its accounts receivable and the processes used to determine their collectability [4] - Defendants claimed to employ an active monitoring process for accounts receivable, which was not the case, as they utilized a 180-day cliff for reserving accounts [4] - The firm also failed to maintain sufficient professional malpractice liability insurance, contrary to its representations, leading to potential investor damages when the truth was revealed [4]